Jupiter Topco LLC Invests $1.01 Million in TransMedics Group, Inc. $TMDX

Jupiter Topco LLC bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, Holdings Channel reports. The institutional investor bought 15,263 shares of the company’s stock, valued at approximately $1,014,000.

A number of other large investors have also bought and sold shares of the business. Parallel Advisors LLC raised its position in TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of TransMedics Group by 4.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after purchasing an additional 88 shares during the last quarter. HighPoint Advisor Group LLC increased its stake in shares of TransMedics Group by 3.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after buying an additional 88 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of TransMedics Group by 2.9% in the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after buying an additional 100 shares during the last quarter. Finally, US Bancorp DE lifted its position in TransMedics Group by 24.2% during the 3rd quarter. US Bancorp DE now owns 533 shares of the company’s stock worth $60,000 after buying an additional 104 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Price Performance

TMDX opened at $89.98 on Friday. The company has a fifty day moving average price of $80.14 and a two-hundred day moving average price of $92.21. The firm has a market capitalization of $3.11 billion, a PE ratio of 23.13 and a beta of 1.90. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. During the same period last year, the company earned $0.92 EPS. The business’s revenue for the quarter was up 20.7% compared to the same quarter last year. As a group, analysts anticipate that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TMDX. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. UBS Group reduced their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 5th. Stifel Nicolaus increased their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, June 18th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $124.18.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.